Binding, presentation and recognition

Ask about this lesson

Peptide binding, peptide presentation and T-cell recognition answer different questions about the same proposed target, and each requires its own evidence.

A peptide is a short protein fragment. Human leukocyte antigen (HLA) can display peptides for inspection by a T-cell receptor (TCR). Keep the exact peptide, HLA allele and tested cell context on every evidence card. An allele is a particular gene version; “HLA-positive” is not enough detail.

The axis is the claim being tested

The word “binding” hides two different contacts. Peptide-to-HLA binding concerns a fragment fitting the display molecule. TCR-to-peptide–HLA binding concerns a receptor contacting that assembled display. Neither contact, by itself, proves a functional response to naturally presenting cancer cells.

SAME PROPOSED TARGET

PEPTIDE + HLA
Is binding predicted
or measured?

HLA PREPARATION
Which associated peptides
were recovered?

TCR + PEPTIDE–HLA
Does this receptor bind
the defined reagent?

NATURAL TARGET
Do tested cells provoke
recognition or function?

These cards compare claims; they are not automatic steps toward success.

Match evidence to the contact and preparation

Evidence	Question and context	Supported claim	Missing claim
Binding prediction	Exact peptide–allele pair, model and output task	A model estimate for that pair	Measured binding or natural display
Measured peptide-to-HLA binding	Defined molecules and assay conditions	Binding under that assay	Processing, cancer-cell display or T-cell function
Immunopeptidomics	Peptides recovered from an HLA preparation	Association with the recovered preparation, subject to identification controls	Guaranteed cancer-cell origin, surface location or complete recovery
Peptide–HLA multimer staining	T cells binding a defined peptide–HLA reagent	Reagent-binding cells under the staining conditions	A peptide-affinity measurement or demonstrated killing
Controlled response to naturally presenting target cells	Specified target cells and appropriate antigen/HLA controls	Recognition or the particular function actually measured	Recognition at every site, safety or patient benefit

Mixed-tissue recovery cannot assign a peptide to cancer cells automatically. A whole-cell HLA preparation can include intracellular complexes. Supplied-peptide stimulation can bypass processing steps; a positive response there is different from testing natural tumor display. For preparation and detection limits, read the existing immunopeptidomics lesson.

Which evidence fits the question?

For a model estimate, use the prediction record. For recovered HLA-associated material, use the preparation and identification record. For natural tumor recognition, use suitable target-cell experiments. None is a universal winner: the question determines the needed evidence, sample and controls. A response assay also needs its actual output named; secretion and target-cell death are different outputs.

Common confusions

A favorable score is not a measured affinity. A recovered peptide is not guaranteed cancer-surface display. Multimer positivity is not a killing result. Recognition, killing, safety and clinical benefit remain distinct even when several findings agree.

Try it: reuse the evidence notebook

Read the fictional notebook and its worked interpretation, then the supplied-peptide exercise and answer. Carry a favorable exact-allele prediction alongside those cards if one is provided; it adds a model estimate, not a natural-target test.

Explain the missing bridge: mixed-tissue peptide recovery and a supplied-peptide response do not establish which cancer cells display the peptide naturally or whether those cells provoke the measured response. The linked answer explains why nondetection also needs assay limits. The allele-mismatch example supplies another context check.

Explain it back

“This binding result concerns ____ contacting ____. It establishes ____, while ____ remains untested.”

For multimer staining: “a T-cell receptor; a peptide–HLA reagent; reagent binding under the assay; natural tumor recognition and killing.”

Takeaway

Keep the contact, preparation and earned claim attached to each result.

Use the design-board lesson to carry these separate evidence fields into a candidate record, and immune-function measurements to distinguish assay outputs.

Sources and scope

Source check: October 12, 2026. Primary abstracts and the linked public lessons informed this claim map. The detailed isolation protocol could not be accessed in this run; its abstract establishes HLA-complex capture and peptide identification, not a complete Methods review. No new performance rates or clinical examples are added. Independent peer, expert and learner review pending.

Reynisson et al., 2020: prediction methods using binding and eluted-ligand data; example methods, not a current software ranking.
Purcell et al., 2019: immunoaffinity capture of HLA-associated peptides from cells and tissues; abstract only here.
Altman et al., 1996: defined peptide–HLA multimers binding antigen-specific T cells.
Wells et al., 2020: predicted candidates compared with patient-matched T-cell binding tests; no natural-tumor or benefit claim follows from this benchmark alone.